Get started
Rigel Pharmaceuticals, Inc.Rigel Pharmaceuticals, Inc.Rigel Pharmaceuticals, Inc.

Rigel Pharmaceuticals, Inc.

No trades
OverviewFinancialsNewsDocumentsCommunityTechnicalsForecastsSeasonalsOptionsETFs

What traders are saying


Join the conversation. Discover trade ideas, share insights, and see how others read the market.
Rigel Pharmaceuticals (RIGL)Gross Margin: ~89% - 92% Sales Growth (Q/Q): ~40% - 60% P/E (Current),~6.1 - 6.3,"Extremely low. The market is still cautious, which offers potential for a ""value"" investment." Forward P/E,~10.8,"Slightly up from current, reflecting expected R&D investments in 2026." Free Cash Flow,~$77M (for 2025),"The company has generated significant cash, ending 2025 with $154.6M in cash." ROE,>200%,"The number is skewed upwards due to the recent move to profitability, but shows tremendous efficiency." Debt/Equity,~0.3 - 0.5,"Low debt, which is excellent for the sector." Revenue Growth,~25% - 60%,2026 forecast is for revenue between $275M and $290M. PEG Ratio,n/a,Most platforms do not calculate this due to recent earnings volatility. Dividend Yield,0%,Typical for biotech; reinvest everything in new developments (e.g. R289). Analyst Rating,Strong Buy,Average analyst target is around $51.20 (potential for +35%).
NASDAQ:RIGLLong
by SimeonNikolaev-invest
1
1/21/25 - RIGL: new BUY mechanical trading signal.1/21/25 - RIGL: new BUY signal chosen by a rules based, mechanical trading system. RIGL - BUY Stop Loss @ 16.25 Entry BUY @ 21.81 Target Profit @ 27.80 Analysis: Higher timeframe: Prices have stayed above the lower channel line of the ATR (Average True Range) Keltner Channel and reversed. Higher timeframe: Victor Sperandeo's (Trader Vic) classic 1-2-3 BUY pattern...where the current lowest bottom breakout price is greater than the preceding bottom price. Higher timeframe: Price peaked below the ATR (Average True Range) breakout low and then reversed.
NASDAQ:RIGLLong
by martinmlm
2
Watchlist 2023-03-07 $OPK $RIGL $WE SPY - flat this morning as we await the second testimonial day for FED chair Powell. There has been lots of opportunity in small caps the past week so shifting focus there, also to avoid the chop that we see in large cap on Fed days. OPK - Opko health sign deal for experimental Epstein-Barr virus vaccine. Triple bottom type of action at the 1.00 level. Showing 3 RVOl in PM. Room to 1.50 level, don’t want to be first. Let some structure develop. Want to see shorts try and try but fail to push this under, that's when im interested. RIGL - beats quarterley top and bottom. Will need some market structure to form. PM HL and pivot support to not align for either. Interested in a long without a support touch only if we hold the 1.85 level for 15-30 min, then start to breakout. Else, looking for support around 1.73, 1.64. 2.20 is the most key resistance area of PM resistance and the bottom channel forming support. WE - gapping over a double top near the ATL after 8 days of consecutive selling. Might have some room to 1.55. Seem like a lot of sellers are done. AAPL - if we see some momo pick up in large caps to the downside, Want to look for shorts in AAPL after and significant triple top at 157 on elevated RVOL
NASDAQ:RIGL
by UnclePennybagss
Rigel Pharmaceuticals doing a thing. RIGLNot quite going to Rigel, but showing more and more promise of higher highs in the not so distant future. Looking quite optimal fractally, actually. Fibonacci goals are in green, reversal or invalidation is in red. This post is not financial advice, make your own financial advice or pay a certified professional ( you are to statistically faire better at blindly longing SnP500 incase of the latter). Playing on the market whether you are an investor or a trader is risky. No good thing is ever without. Good luck out there.
NASDAQ:RIGLLong
by Rykin_Capital
$RIGL can rise in the next daysContextual immersion trading strategy idea. Rigel Pharmaceuticals, Inc., a biotechnology company, engages in the discovery and development of small molecule drugs for the treatment of immune and hematologic disorders, cancer, and rare diseases. The demand for shares of the company looks higher than the supply. This and other conditions can cause a rise in the share price in the next days. So I opened a long position from $3,71; stop-loss — $3,19. Information about take-profits will be later. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
NASDAQ:RIGLShort
by KozakHlib
$RIGL can rise in the next daysContextual immersion trading strategy idea. Rigel Pharmaceuticals, Inc., a biotechnology company, engages in the discovery and development of small molecule drugs for the treatment of immune and hematologic disorders, cancer, and rare diseases. The share prose rose after the company had announced that a drug used to treat an autoimmune disorder will be tested in a clinical trial in the United Kingdom as a treatment for COVID-19 pneumonia. The demand for shares of the company still looks higher than the supply. These and other conditions can cause a rise in the share price in the next days. So I opened a long position from $2,19; stop-loss — $2,00. Information about take-profits will be later. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
NASDAQ:RIGLLong
by KozakHlib
Investigator-Sponsored Trial of FostamatinibRigel Announces Investigator-Sponsored Trial of Fostamatinib in Patients with COVID-19 Pneumonia. High content screen identifies fostamatinib as a candidate for repurposing for Acute Lung Injury. The hallmark of severe COVID-19 is hypoxemia and a radiological pattern of acute lung injury (ALI) that shares features with ARDS. By inhibiting SYK, fostamatinib may specifically inhibit the infiltration and activation of monocytes and neutrophils in the lungs that are prominent in COVID-19. www.prnewswire.com
NASDAQ:RIGL
by AlenCiken